De novo HDAC3 variants leading to epigenetic machinery dysfunction are associated with a neurodevelopmental disorder

Abstract

Histone deacetylase 3 (HDAC3) is a crucial epigenetic modulator essential for brain development. Although its dysfunction is increasingly recognized in various neurodevelopmental disorders, there have been no reports of human diseases related to HDAC3 dysfunction in Online Mendelian Inheritance in Man (OMIM). This study establishes a novel link between heterozygous de novo variants in HDAC3 and a distinct neurodevelopmental syndrome, characterized by intellectual disability, developmental delays, and other variable manifestations such as musculoskeletal anomalies and congenital heart defects. In a cohort of six individuals, we identified de novo missense HDAC3 variants (D93N, A110T, P201S, L266S, G267S, and R359C), all located in evolutionarily conserved sites. Using trio exome sequencing and extensive phenotypic analysis, we correlated these genetic alterations with the observed clinical spectrum. Our investigations using HDAC assays and western blot analyses identified reduced deacetylation activity in the L266S and G267S variants, positioned near the enzymatic pocket. Additionally, proteomic analysis employing co-immunoprecipitation revealed that disrupted interactions with key multi-protein complexes, particularly CoREST and NCoR in the A110T variant, suggesting a critical pathogenic mechanism. Moreover, immunofluorescence analysis revealed diminished fluorescence intensity (nuclear to cytoplasmic ratio) in the A110T, G267S, and R359C variants, indicating impaired nuclear localization. This study highlights that de novo HDAC3 variants are associated with a novel neurodevelopmental syndrome, emphasizing the importance of histone deacetylase activity, multi-protein complex interactions, and nuclear localization for normal cellular function of HDAC3. These insights open new possibilities for understanding the molecular mechanisms of this uncharacterized neurodevelopmental disorder and may inform future therapeutic approaches.

• Download figure
• Open in new tab

Graphical abstractThis study identifies de novo HDAC3 variants in patients with neurodevelopmental disorders, characterized by intellectual disability, developmental delays, and other variable manifestations. We demonstrate that these variants result in reduced HDAC activity, compromised interactions with multi-protein complexes, and improper nuclear localization of the HDAC3 protein. This provides a novel gene-disease association and offers insights into the molecular underpinnings of this disorder.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported by the Institute of Information & Communications Technology Planning & Evaluation (IITP) grant, funded by the Korean government (MSIT, grant numbers: 2022-0-00333, RS-2023-00223069). Also, it was supported by the National Research Foundation of Korea (NRF) grants (NRF2021R1C1C1013220, NRF2022R1A5A102641311, and NRF2020R1A5A1019023), and the BK21 Four Biomedical Science Program. The SNUH Kun-hee Lee Child Cancer and Rare Disease Project Foundation, Republic of Korea (grant number: 22B-001-0100), the Research Resettlement Fund for the new faculty of Seoul National University, the Creative-Pioneering Researchers Program through Seoul National University, grants from Seoul National University College of Medicine, and the AI-Bio Research Grant through Seoul National University also supported this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study received approval from the Institutional Review Boards of the participating institutions (Seoul National University Hospital, SNUH IRB No. 1406-081-588) in compliance with the Declaration of Helsinki.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes